ArticleFrontiers in microbiology2021
Harringtonine Inhibits Herpes Simplex Virus Type 1 Infection by Reducing Herpes Virus Entry Mediator Expression.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Recurrence of acyclovir-resistant herpes encephalitis in an immunocompromised patient: A case report.World journal of clinical cases · 2025Article
- Quercetin inhibits herpes simplex virus 1 replication in corneal epithelium and suppresses keratitis progression.Virologica Sinica · 2025Article
- 6-thioguanine inhibits EV71 replication by reducing BIRC3-mediated autophagy.BMC microbiology · 2025Article
- An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application.Virulence · 2024Review
- Immunological Considerations for the Development of an Effective Herpes Vaccine.Microorganisms · 2024Review
- Herpes simplex keratitis: A brief clinical overview.World journal of virology · 2024Review
- Molecular insights into the inhibition mechanism of harringtonine against essential proteins associated with SARS-CoV-2 entry.International journal of biological macromolecules · 2023Article
- A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV.Cureus · 2023Review
- Quindoline-derivatives display potent G-quadruplex-mediated antiviral activity against herpes simplex virus 1.Antiviral research · 2022Article
- Clinical Management of Herpes Simplex Virus Keratitis.Diagnostics (Basel, Switzerland) · 2022Review
- Herpesvirus-Associated Encephalitis: an Update.Current tropical medicine reports · 2022Review
- PKHB1 peptide induces antiviral effects through induction of immunogenic cell death in herpes simplex keratitis.Frontiers in pharmacology · 2022Article
- Medicinal plants and natural compounds against acyclovir-resistant HSV infections.Frontiers in microbiology · 2022Review
- Nectin-1 and Non-muscle Myosin Heavy Chain-IIB: Major Mediators of Herpes Simplex Virus-1 Entry Into Corneal Nerves.Frontiers in microbiology · 2022Article
- Overcoming Resistance: A Comprehensive Review and Treatment Approach for Acyclovir-Resistant Herpes Simplex Keratitis.Journal of current ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 1 (HSV-1) infection induces various clinical disorders, such as herpes simplex encephalitis (HSE), herpes simplex keratitis (HSK), and genital herpes. In clinical intervention, acyclovir (ACV) is the major therapeutic drug used to suppress HSV-1; however, ACV-resistant strains have gradually increased. In the present study, harringtonine (HT) significantly inhibited infection of HSV-1 as well as two ACV-resistant strains, including HSV-1 blue and HSV-1 153. Time-of-drug addition assay further revealed that HT mainly reduced the early stage of HSV-1 infection. We also demonstrated that HT mainly affected herpes virus entry mediator (HVEM) expression as shown by qPCR, Western Blot, and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.